Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Dasatinib is an efficient therapy for central nervous system Philadelphia chromosome-positive mixed phenotype acute leukemia].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi - 1 Nov 2014

Lin Dong, Zhou Chunlin, Liu Bingcheng, Lyu Rui, Wang Jinyu, Mi Yingchang, Wang Jianxiang

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Central Nervous System
Share to Dasatinib
Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Pyrimidines

Share to Thiazoles

Source

Identifiers

PMID: 25417882
DOI: 10.3760/cma.j.issn.0253-2727.2014.11.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Dasatinib is an efficient therapy for central nervous system Philadelphia chromosome-positive mixed phenotype acute leukemia].PMID 25417882Read ↗

Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.Semantic proximity Read ↗

Dasatinib treatment for Philadelphia chromosome‐positive leukemiasSemantic proximity Read ↗

Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemiaSemantic proximity Read ↗

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.Semantic proximity Read ↗

Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.Semantic proximity Read ↗

Prophylactic and Preemptive Therapy with Dasatinib after Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.Semantic proximity Read ↗

Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up resultsSemantic proximity Read ↗

Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status.Semantic proximity Read ↗

Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.Semantic proximity Read ↗

Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report.Semantic proximity Read ↗

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.